This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Covidien Beats, Reaffirms Guidance

Stocks in this article: COV ANPI BSX BCR CFN

DUBLIN, Ireland ( TheStreet) -- Covidien (COV) shares jumped several points amid heavy trading Tuesday morning after the medical supplies maker beat quarterly expectations and reaffirmed its 2011 revenue guidance.

Covidien said strengthened demand for its medical devices helped drive results. A lower tax rate, less restructuring-related costs and strong sales of the company's vascular devices and patient monitoring products also helped the company's improved performance in the recent quarter.

Covidien booked a 3.6% increase in quarterly net profits to $427 million, or 86 cents per share, up from year-earlier earnings of $412 million, or 82 cents per share.

Revenue increased 5% to $2.77 billion, from $2.64 billion.

Excluding one-time gains related to inventory and restructuring charges, Covidien said it earned 95 cents per share from continuing operations, up from 84 cents per share in the first fiscal quarter last year.

Top- and bottom-line results beat analysts' consensus call for earnings of $403.1 million, or 81 cents per share, on revenue of $2.73 billion. Analysts typically exclude one-time items when forecasting estimates.

"Solid medical device sales results likely helped by continued strong performance of recent acquisitions more than offset some softness in the medical supplies business," noted Leerink Swann analyst Rick Wise.

Deutsche Bank analysts noted that results at Covidien's medical devices and pharmaceutical units were "very good," and the firm was "not concerned" about weakened performance at its medical supplies division.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs